Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

Item

http://www.wikidata.org/entity/Q28546940

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@ast

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@en

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@nl

type

Item

label

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@ast

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@en

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@nl

prefLabel

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@ast

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@en

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@nl

P1476

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major

@en

P2093

Kimbra G Turner

http://www.w3.org/2001/XMLSchema#string

Maricela Robles-Murguia

http://www.w3.org/2001/XMLSchema#string

Mariha Wadsworth

http://www.w3.org/2001/XMLSchema#string

Mary Ann McDowell

http://www.w3.org/2001/XMLSchema#string

Miguel A Morales

http://www.w3.org/2001/XMLSchema#string

Paola Vacchina

http://www.w3.org/2001/XMLSchema#string

P2860

Leishmaniasis worldwide and global estimates of its incidence

Leishmaniasis: current status of available drugs and new potential drug targets

Clustal W and Clustal X version 2.0

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden

Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis

Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol

LmaPA2G4, a homolog of human Ebp1, is an essential gene and inhibits cell proliferation in L. major

P304

e0003948

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

710330

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PNTD.0003948

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280581208

http://www.w3.org/2001/XMLSchema#string

P698

26230675

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

4521777

http://www.w3.org/2001/XMLSchema#string